Frei N.F.a· Stachler M.D.b

Author affiliations

aDepartment of Gastroenterology and Hepatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
bDepartment of Pathology, University of California, San Francisco, CA, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: October 28, 2021
Accepted: December 27, 2021
Published online: February 02, 2022

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 1

ISSN: 2297-4725 (Print)
eISSN: 2297-475X (Online)

For additional information: https://www.karger.com/VIS

Abstract

Background: A histological diagnosis of dysplasia is our current best predictor of progression in Barrett’s esophagus (BE), the precursor of esophageal adenocarcinoma (EAC). Despite periodic endoscopic surveillance and assessment of dysplastic changes, we fail to identify the majority of those who progress before the development of EAC, whereas the majority of patients undergo endoscopy without showing progression. Summary: Low-grade dysplasia (LGD), confirmed by expert pathologists, identifies BE patients at higher risk for progression, but the diagnosis of LGD is challenging. Recent research indicates that progression from BE to EAC is heterogeneous and can accelerate via genome doubling and genome catastrophes, resulting in different ways to progression. We identified 3 target areas, which may help to overcome the current lack of an accurate biomarker: (1) the implementation of somatic point mutations, chromosomal alterations, and epigenetic changes (genomics and epigenomics), (2) evaluate and develop biomarkers over space and time, (3) use new sampling methods such as noninvasive self-expandable sponges and endoscopic brushes. This review focus on the state of the art in risk stratifying BE and on recent advances which may overcome the limitations of current strategies. Key Messages: A panel of clinical factors, genomics, epigenomics, and/or proteomics will most likely lead to an assay that accurately risk stratifies BE patients into low- or high-risk for progression. This biomarker panel needs to be developed and validated in large cohorts containing a sufficient number of progressors, with testing samples over space (spatial distribution) and time (temporal distribution). For implementation in clinical practice, the technique should be affordable and applicable to formalin-fixed paraffin-embedded samples, which represent standard of care.

© 2022 S. Karger AG, Basel

References Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598. Reid BJ, Paulson TG, Li X. Genetic insights in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2015;149:1142–52.e3. Krishnamoorthi R, Singh S, Ragunathan K, Visrodia K, Wang KK, Katzka DA, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1046–55.e8. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–83. Klaver E, Bureo Gonzalez A, Mostafavi N, Mallant‐Hent R, Duits LC, Baak B, et al. Barrett’s esophagus surveillance in a prospective Dutch multi‐center community‐based cohort of 985 patients demonstrates low risk of neoplastic progression. United European Gastroenterol J. 2021;9(8):929–37. Dong J, Maj C, Tsavachidis S, Ostrom QT, Gharahkhani P, Anderson LA, et al. Sex-specific genetic associations for Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2020;159:2065–76.e1. Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, et al. Germline variation in inflammation-related pathways and risk of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut. 2017;66:1739–47. Xie SH, Fang R, Huang M, Dai J, Thrift AP, Anderson LA, et al. Association between levels of sex hormones and risk of esophageal adenocarcinoma and Barrett’s esophagus. Clin Gastroenterol Hepatol. 2020;18:2701–9.e3. Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;21:36–51. Münch NS, Fang HY, Ingermann J, Maurer HC, Anand A, Kellner V, et al. High-fat diet accelerates carcinogenesis in a mouse model of Barrett’s esophagus via interleukin 8 and alterations to the gut microbiome. Gastroenterology. 2019;157:492–506.e2. Wani S, Rubenstein JH, Vieth M, Bergman J. Diagnosis and management of low-grade dysplasia in Barrett’s esophagus: expert review from the clinical practice updates committee of the American Gastroenterological Association. Gastroenterology. 2016;151:822–35. Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64:700–6. Duits LC, van der Wel MJ, Cotton CC, Phoa KN, Ten Kate FJW, Seldenrijk CA, et al. Patients with Barrett’s esophagus and confirmed persistent low-grade dysplasia are at increased risk for progression to neoplasia. Gastroenterology. 2017;152:993–1001.e1. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang J-Y, Watson P. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42. Snyder P, Dunbar K, Cipher DJ, Souza RF, Spechler SJ, Konda VJA. Aberrant p53 immunostaining in Barrett’s esophagus predicts neoplastic progression: systematic review and meta-analyses. Dig Dis Sci. 2019;64:1089–97. Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut. 2013;62:1676–83. Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, et al. Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology. 2018;155:156–67. van der Wel MJ, Coleman HG, Bergman JJGHM, Jansen M, Meijer SL; BOLERO working group. Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett’s dysplasia using digital pathology. Gut. 2020;69:811–22. Killcoyne S, Gregson E, Wedge DC, Woodcock DJ, Eldridge MD, de la Rue R, et al. Genomic copy number predicts esophageal cancer years before transformation. Nat Med. 2020;26:1726–32. Contino G, Vaughan TL, Whiteman D, Fitzgerald RC. The evolving genomic landscape of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2017;153:657–73.e1. Nowicki-Osuch K, Zhuang L, Jammula S, Bleaney CW, Mahbubani KT, Devonshire G, et al. Molecular phenotyping reveals the identity of Barrett’s esophagus and its malignant transition. Science. 2021;373(6556):760–7. Kunze B, Wein F, Fang HY, Anand A, Baumeister T, Strangmann J, et al. Notch signaling mediates differentiation in Barrett’s esophagus and promotes progression to adenocarcinoma. Gastroenterology. 2020;159:575–90. Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, et al. Paired exome analysis of Barrett’s esophagus and adenocarcinoma. Nat Genet. 2015;47:1047–55. The OCCAMS Consortium; Weaver JMJ, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet. 2014;46:837–43. Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, et al. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis. 2014;35:2740–7. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38:468–73. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett’s esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology. 1987;93:1–11. Hadjinicolaou AV, van Munster SN, Achilleos A, Santiago Garcia J, Killcoyne S, Ragunath K, et al. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett’s oesophagus: a multi-centre prospective cohort study. EBioMedicine. 2020;56:102765. Fritcher EGB, Brankley SM, Kipp BR, Voss JS, Campion MB, Morrison LE, et al. A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett’s esophagus. Hum Pathol. 2008;39:1128–35. Timmer MR, Martinez P, Lau CT, Westra WM, Calpe S, Rygiel AM, et al. Derivation of genetic biomarkers for cancer risk stratification in Barrett’s oesophagus: a prospective cohort study. Gut. 2016;65:1602–10. Bajpai M, Panda A, Birudaraju K, Van Gurp J, Chak A, Das KM, et al. Recurring translocations in Barrett’s esophageal adenocarcinoma. Front Genet. 2021;12:674741. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001;61:3410–8. Kaz AM, Grady WM, Stachler MD, Bass AJ. Genetic and epigenetic alterations in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 2015;44:473–89. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009;69:4112–5. Alvi MA, Liu X, O’Donovan M, Newton R, Wernisch L, Shannon NB, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus. Clin Cancer Res. 2013;19:878–88. Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci Transl Med. 2018;10:eaao5848. Redston M, Noffsinger A, Kim A, Akarca FG, Rara M, Stapleton D, et al. Abnormal TP53 predicts risk of progression in patients with Barrett’s esophagus regardless of a diagnosis of dysplasia. Gastroenterology. 2021. Epub ahead of print. Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology. 2012;143:927–35.e3. Davison JM, Goldblum J, Grewal US, McGrath K, Fasanella K, Deitrick C, et al. Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s esophagus. Am J Gastroenterol. 2020;115:843–52. Frei NF, Khoshiwal AM, Konte K, Bossart EA, Stebbins K, Zhang Y, et al. Tissue systems pathology test objectively risk stratifies Barrett’s esophagus patients with low-grade dysplasia. Am J Gastroenterol. 2021;116:675–82. Frei NF, Konte K, Bossart EA, Stebbins K, Zhang Y, Pouw RE, et al. Independent validation of a tissue systems pathology assay to predict future progression in nondysplastic Barrett’s esophagus: a spatial-temporal analysis. Clin Transl Gastroenterol. 2020;11:e00244. Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett’s esophagus. Cancer Prev Res. 2014;7:114–27. Li X, Paulson TG, Galipeau PC, Sanchez CA, Liu K, Kuhner MK, et al. Assessment of esophageal adenocarcinoma risk using somatic chromosome alterations in longitudinal samples in Barrett’s esophagus. Cancer Prev Res. 2015;8:845–56. Codipilly DC, Krishna Chandar A, Wang KK, Katzka DA, Goldblum JR, Thota PN, et al. Wide-area transepithelial sampling for dysplasia detection in Barrett’s esophagus: a systematic review and meta-analysis. Gastrointest Endosc. 2022 Jan;95(1):51–9.e7. Douville C, Moinova HR, Thota PN, Shaheen NJ, Iyer PG, Canto MI, et al. Massively parallel sequencing of esophageal brushings enables an aneuploidy-based classification of patients with Barrett’s esophagus. Gastroenterology. 2021;160:2043–54.e2. Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, et al. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. 2017;2:23–31. Article / Publication Details

First-Page Preview

Received: October 28, 2021
Accepted: December 27, 2021
Published online: February 02, 2022

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 1

ISSN: 2297-4725 (Print)
eISSN: 2297-475X (Online)

For additional information: https://www.karger.com/VIS

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.